Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327645 | 0.88 | ACACB (0.31) | ACACB | |
| SCHEMBL2610533 | 0.85 | AKT1 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL10310591 | 0.84 | ALDH1A1 (0.35) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL2610530 | 0.82 | POLB (0.36) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL10050026 | 0.82 | SMN1; SMN2 (0.37) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL10037571 | 0.80 | POLB (0.37) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL13185397 | 0.80 | POLB (0.37) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL13448309 | 0.79 | POLB (0.35) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL12107536 | 0.78 | CYP1A2 (0.43) | SMN1; SMN2HTTALOX15MAPK1POLB | |
| SCHEMBL10310647 | 0.76 | POLB (0.35) | SMN1; SMN2HTTALOX15MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120244597-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-8247536-B2 | Factor VIII compositions | NEKTAR THERAPEUTICS (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-8133977-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
| US-20110171164-A1 | POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130427-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | BCHE, ACHE, DNPEP | SMN1; SMN2 999/4885HTT 2007/4885ALOX15 2162/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SMN1; SMN2 1435/4885HTT 2560/4885ALOX15 2864/4885 |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NGLY1, VIP, IAPP | SMN1; SMN2 1670/4885HTT 1909/4885ALOX15 2538/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SMN1; SMN2 2381/4885HTT 2129/4885ALOX15 2571/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | SMN1; SMN2 2555/4885HTT 1443/4885ALOX15 4659/4885 |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NGLY1, IAPP, NPSR1 | SMN1; SMN2 958/4885HTT 208/4885ALOX15 3066/4885 |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SMN1; SMN2 2365/4885HTT 2131/4885ALOX15 2595/4885 |
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | SOST, PTMS, ALPP | SMN1; SMN2 3235/4885HTT 2716/4885ALOX15 4228/4885 |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | OGFR, OGFRL1, OPRL1 | SMN1; SMN2 1583/4885HTT 1367/4885ALOX15 2287/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | SMN1; SMN2 164/4885HTT 909/4885ALOX15 3969/4885 |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SMN1; SMN2 2365/4885HTT 2131/4885ALOX15 2595/4885 |
| US-20100130427-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SMN1; SMN2 1402/4885HTT 2510/4885ALOX15 2934/4885 |
| US-20110171164-A1 | POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES | IAPP, GLP1R, GIPR | SMN1; SMN2 2167/4885HTT 448/4885ALOX15 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.